Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Scott

Showing results (311-320 of 327) with videos related to

Pageof 33
Sort By:
Elife|January 30, 2018
Prediction of enzymatic pathways by integrative pathway mappingSara Calhoun, Magdalena Korczynska, Daniel J Wichelecki, et al.
Journal of Medicinal Chemistry|July 24, 2008
Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinasesTao Wang, Michelle L Lamb, David A Scott, et al.
Cancer Research|October 10, 2018
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast CancerZebin Wang, Shaun E Grosskurth, Tony Cheung, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Bioorganic & Medicinal Chemistry Letters|November 8, 2015
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clusteringJeffrey W Johannes, Lynsie Almeida, Kevin Daly, et al.
Elife|December 7, 2021
Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer BiologyTimothy M Errington, Alexandria Denis, Anne B Allison, et al.
Nature Communications|May 20, 2022
Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editingColin McGaw, Anthony J Garrity, Gabrielle Z Munoz, et al.
Science Advances|July 3, 2024
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulationDheeraj Soni, Francesco Borriello, David A Scott, et al.
ANZ Journal of Surgery|May 10, 2022
Achieving safe surgery after COVID-19 vaccinationJoshua G Kovoor, Jonathan Henry W Jacobsen, Joanna Duncan, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated responseRuby Pandher, Chengyuan Xue, Laura D Gamble, et al.
Pageof 33

Showing results (311-320 of 327) with videos related to

Sort By:
Pageof 33
Elife|January 30, 2018
Prediction of enzymatic pathways by integrative pathway mappingSara Calhoun, Magdalena Korczynska, Daniel J Wichelecki, et al.
Journal of Medicinal Chemistry|July 24, 2008
Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinasesTao Wang, Michelle L Lamb, David A Scott, et al.
Cancer Research|October 10, 2018
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast CancerZebin Wang, Shaun E Grosskurth, Tony Cheung, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Bioorganic & Medicinal Chemistry Letters|November 8, 2015
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clusteringJeffrey W Johannes, Lynsie Almeida, Kevin Daly, et al.
Elife|December 7, 2021
Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer BiologyTimothy M Errington, Alexandria Denis, Anne B Allison, et al.
Nature Communications|May 20, 2022
Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editingColin McGaw, Anthony J Garrity, Gabrielle Z Munoz, et al.
Science Advances|July 3, 2024
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulationDheeraj Soni, Francesco Borriello, David A Scott, et al.
ANZ Journal of Surgery|May 10, 2022
Achieving safe surgery after COVID-19 vaccinationJoshua G Kovoor, Jonathan Henry W Jacobsen, Joanna Duncan, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated responseRuby Pandher, Chengyuan Xue, Laura D Gamble, et al.
Pageof 33